Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for organ fibrosis and inflammatory diseases. Operating through its majority-owned subsidiary Gyre Pharmaceuticals in the PRC and U.S. headquarters in San Diego, CA, its commercial portfolio includes ETUARY (pirfenidone) for IPF, Etorel (nintedanib) for IPF and ILD, and Contiva (avatrombopag) for thrombocytopenia. Its lead pipeline candidate, Hydronidone (F351), targets liver fibrosis in CHB and MASH indications.
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-13 | 2025-12-31 | 0001193125-26-106251 | EDGAR | 126K words |
| 2025-03-17 | 2024-12-31 | 0000950170-25-040279 | EDGAR | 123K words |
| 2024-03-27 | 2023-12-31 | 0000950170-24-037242 | EDGAR | 126K words |
| 2023-03-30 | 2022-12-31 | 0001564590-23-004830 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001564590-22-012877 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001564590-21-010823 | EDGAR | — |
| 2020-02-20 | 2019-12-31 | 0001564590-20-005546 | EDGAR | — |
| 2019-03-08 | 2018-12-31 | 0001564590-19-006879 | EDGAR | — |
| 2018-03-19 | 2017-12-31 | 0001564590-18-006216 | EDGAR | — |
| 2017-03-08 | 2016-12-31 | 0001564590-17-003722 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-07 | 2026-06-30 | 0001193125-26-340448 | EDGAR | 38K words |
| 2025-11-07 | 2025-09-30 | 0001193125-25-272383 | EDGAR | 31K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106644 | EDGAR | 29K words |
| 2025-05-09 | 2025-03-31 | 0000950170-25-068089 | EDGAR | 25K words |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126306 | EDGAR | 28K words |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096159 | EDGAR | 27K words |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058642 | EDGAR | 22K words |
| 2023-10-26 | 2023-09-30 | 0000950170-23-055695 | EDGAR | 22K words |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042218 | EDGAR | 20K words |
| 2023-05-15 | 2023-03-31 | 0001564590-23-007276 | EDGAR | 17K words |
| 2022-11-14 | 2022-09-30 | 0001564590-22-037555 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001564590-22-029487 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-01 | 0001140361-26-035189 | EDGAR | 3K words |
| 2026-08-26 | 0001140361-26-034401 | EDGAR | 4K words |
| 2026-08-07 | 0001193125-26-339223 | EDGAR | 6K words |
| 2026-07-16 | 0001140361-26-028716 | EDGAR | 1K words |
| 2026-03-23 | 0001140361-26-010654 | EDGAR | 1K words |
| 2026-03-12 | 0001140361-26-009115 | EDGAR | 1K words |
| 2026-03-12 | 0001193125-26-102700 | EDGAR | 5K words |
| 2026-03-02 | 0001140361-26-007249 | EDGAR | 4K words |
| 2026-01-05 | 0001140361-26-000253 | EDGAR | 1K words |
| 2025-11-07 | 0001193125-25-270524 | EDGAR | 5K words |
323 total filings indexed. 291 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001124105 |
| Ticker | GYRE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | San Diego, California |
| Website | https://www.gyretx.com |
| Listed | 2023-10-31 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GYRE (~200 tokens, structured JSON with cryptographic provenance)